Key facts
- This page summarizes Edward J. Sitar's Form 4 filing for Timber Pharmaceuticals, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Apr 2023, 11:33.
Edward J. Sitar - 15 Apr 2023 Form 4 Insider Report for Timber Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 15 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2023, 11:33:46 UTC
- Prior SEC filing
- 16 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Lucchese, Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Edward J. Sitar filed Form 4 for Timber Pharmaceuticals, Inc. on 18 Apr 2023.
Change
- Previous filing in this sequence was filed on 16 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMBR
transaction
Common Stock, par value $0.001 per share
Award
- Transaction value
- $0
- Shares
- +5,327
- Change %
- +92%
- Price
- $0.000000
- Shares after
- 11,127
- Date
- 15 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMBR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +5,327
- Change %
- Price
- $0.000000
- Shares after
- 5,327
- Date
- 15 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,327
- Exercise price
- $1.66
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On April 15, 2023, the Reporting Person was granted 5,327 restricted stock units, which will be settled in shares of common stock, par value $0.001. The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.
Footnote F2
25% of the options vest on April 15, 2024, and the remaining shares will become exercisable in 36 equal monthly installments beginning on May 15, 2024, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date.